These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30007459)

  • 1. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
    Butterfield JH; Ravi A; Pongdee T
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
    Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
    Castells M; Butterfield J
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased leukotriene E4 excretion in systemic mastocytosis.
    Butterfield JH
    Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia.
    Giannetti MP; Godwin G; Weller E; Butterfield JH; Castells M
    J Allergy Clin Immunol; 2022 Nov; 150(5):1225-1227. PubMed ID: 35550148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.
    Hamilton MJ
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):469-481. PubMed ID: 30007464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH; Weiler CR
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.
    Voelker D; Pongdee T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):33-38. PubMed ID: 38236528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of mast cell degranulation.
    Hogan AD; Schwartz LB
    Methods; 1997 Sep; 13(1):43-52. PubMed ID: 9281467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Expression of Mast Cell Activation Disorders.
    Broesby-Olsen S; Carter M; Kjaer HF; Mortz CG; Møller MB; Kristensen TK; Bindslev-Jensen C; Agertoft L
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):365-377. PubMed ID: 30007457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
    Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
    Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
    Gülen T; Möller Westerberg C; Lyberg K; Ekoff M; Kolmert J; Bood J; Öhd J; James A; Dahlén SE; Nilsson G; Dahlén B
    Clin Exp Allergy; 2017 Jul; 47(7):909-917. PubMed ID: 28258965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How good are mast cell mediators?
    Weiler CR
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):410-411. PubMed ID: 34303837
    [No Abstract]   [Full Text] [Related]  

  • 20. Mast cell activation: beyond histamine and tryptase.
    Theoharides TC; Perlman AI; Twahir A; Kempuraj D
    Expert Rev Clin Immunol; 2023 Jun; 19(6):639-654. PubMed ID: 37029958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.